Mauna Kea Technologies appoints its new Managing Director: Sacha Loiseau – 2022-10-04 at 18:15


(AOF) – The founder and current Chairman of the Board of Directors of Mauna Kea Technologies, Sacha Loiseau, will once again hold the position of Managing Director. He replaces Nicolas Bouvier, interim Chief Executive Officer, while combining the functions of Chairman and Chief Executive Officer. Co-founder of Mauna Kea Technologies, he was its CEO for more than 18 years, taking the company public in July 2011 on Euronext.

AOF – LEARN MORE

An inevitable race for new blockbusters

The patent for Merck’s star product, the cancer drug Keytruda, which accounts for more than 35% of its sales, expires in 2028. Despite the loss, since 2019, of the patents for its three star products (Avastin, Herceptine, Rituxan) Roche was able to renew its portfolio by bringing new molecules to market. However, the discovery and launch of new drugs are increasingly expensive. AstraZeneca spends about $6 billion a year on R&D in a pharmaceutical industry where the life of a patent only lasts ten to fifteen years. This leads laboratories to withdraw from certain activities. Thus J&J, Pfizer, GSK and, no doubt, Novartis soon prefer to refocus on specialty drugs and abandon any ancillary activity.



Source link -86